01228.HK
CANbridge Pharmaceuticals Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 1.77
−0.56%Year over year
Reported trailing growth
- Revenue
- -11.0%
- EBITDA
- +41.6%
- EBIT
- +39.4%
- EPS
- +50.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.1%
- EBITDA
- +74.3%
- EBIT
- +72.8%
- Net income
- +103.3%
- EPS
- +102.9%
- Free cash flow
- +68.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026